Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | KDM4A | O75164 | 11/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21698588 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRDNM1KDM4AKDM4C | |
| SCHEMBL23655783 | 0.82 | — | — | |
| SCHEMBL23656237 | 0.79 | PAOX (0.39) | ALDH1A1KDM4CKDM5APAOX | |
| SCHEMBL23761749 | 0.79 | — | — | |
| SCHEMBL21937171 | 0.78 | LSS (0.49) | ALDH1A1TSHRDNM1KDM4AKDM4C | |
| SCHEMBL23011695 | 0.78 | LSS (0.49) | ALDH1A1TSHRDNM1KDM4AKDM4C | |
| SCHEMBL21308452 | 0.77 | — | — | |
| SCHEMBL19085564 | 0.76 | DNM1 (0.44) | ALDH1A1TSHRDNM1PAOX | |
| SCHEMBL1615108 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRDNM1KDM4AKDM4C | |
| SCHEMBL25668342 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GIPR, GCGR | ALDH1A1 3429/4885TSHR 202/4885DNM1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.